Obesity and Atherosclerosis: Mechanistic Insights

Canadian Journal of Cardiology

Volumn 31, Issue 2, 2015, Pages 177-183

  Lovren, Fina ^a   Teoh, Hwee ^a   Verma, Subodh ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; INFLAMMASOME;

ATHEROSCLEROSIS; AUTOPHAGY; CARDIOVASCULAR RISK; ENDOTHELIAL DYSFUNCTION; HUMAN; INTESTINE FLORA; MACROPHAGE; OBESITY; OXIDATIVE STRESS; REVIEW; RISK ASSESSMENT; VASCULITIS; ADIPOSE TISSUE; COMPLICATION; ENERGY METABOLISM; HOMEOSTASIS; METABOLISM;

ADIPOSE TISSUE; ATHEROSCLEROSIS; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; OBESITY;

EID: 84924958675     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.11.031     Document Type: Review

References (69)

1. Lau D.C., Dhillon B., Yan H., Szmitko P.E., Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 2005, 288:H2031-H2041.
2. Yamauchi T., Kadowaki T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab 2013, 17:185-196.
3. Chen H., Montagnani M., Funahashi T., Shimomura I., Quon M.J. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. JBiol Chem 2003, 278:45021-45026.
4. Motoshima H., Wu X., Mahadev K., Goldstein B.J. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Comm 2004, 315:264-271.
5. Ouchi N., Kihara S., Arita Y., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100:2473-2476.
6. Ouchi N., Kihara S., Arita Y., et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001, 103:1057-1063.
7. Furukawa K., Hori M., Ouchi N., et al. Adiponectin down-regulates acyl-coenzyme A:cholesterol acyltransferase-1 in cultured human monocyte-derived macrophages. Biochem Biophys Res Comm 2004, 317:831-836.
8. Lovren F., Pan Y., Quan A., et al. Adiponectin primes human monocytes into alternative anti-inflammatory M2 macrophages. Am J Physiol Heart Circ Physiol 2010, 299:H656-H663.
9. Arita Y., Kihara S., Ouchi N., et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002, 105:2893-2898.
10. Kumada M., Kihara S., Ouchi N., et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004, 109:2046-2049.
11. Teoh H., Quan A., Bang K.W., et al. Adiponectin deficiency promotes endothelial activation and profoundly exacerbates sepsis-related mortality. Am J Physiol Endocrinol Metab 2008, 295:E658-E664.
12. Matsuda M., Shimomura I., Sata M., et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. JBiol Chem 2002, 277:37487-37491.
13. Okamoto Y., Kihara S., Ouchi N., et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002, 106:2767-2770.
14. Bokarewa M., Nagaev I., Dahlberg L., Smith U., Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. JImmunol 2005, 174:5789-5795.
15. Silswal N., Singh A.K., Aruna B., et al. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Comm 2005, 334:1092-1101.
16. Choi H.Y., Kim S., Yang S.J., et al. Association of adiponectin, resistin, and vascular inflammation: analysis with 18F-fluorodeoxyglucose positron emission tomography. Arterioscler Thromb Vasc Biol 2011, 31:944-949.
17. Verma S., Li S.H., Wang C.H., et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003, 108:736-740.
18. La Cava A., Matarese G. The weight of leptin in immunity. Nat Rev Immunol 2004, 4:371-379.
19. Friedman J.M., Halaas J.L. Leptin and the regulation of body weight in mammals. Nature 1998, 395:763-770.
20. Wu K.K., Huan Y. Diabetic atherosclerosis mouse models. Atherosclerosis 2007, 191:241-249.
21. Lord G.M., Matarese G., Howard J.K., et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998, 394:897-901.
22. Chen W.Q., Zhong L., Zhang L., et al. Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels. Br J Pharmacol 2009, 156:941-951.
23. Hill B.G., Haberzettl P., Ahmed Y., Srivastava S., Bhatnagar A. Unsaturated lipid peroxidation-derived aldehydes activate autophagy in vascular smooth-muscle cells. Biochem J 2008, 410:525-534.
24. Mueller M.A., Beutner F., Teupser D., Ceglarek U., Thiery J. Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia. Atherosclerosis 2008, 198:39-48.
25. Ouimet M., Franklin V., Mak E., et al. Autophagy regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase. Cell Metab 2011, 13:655-667.
26. Lim Y.M., Lim H., Hur K.Y., et al. Systemic autophagy insufficiency compromises adaptation to metabolic stress and facilitates progression from obesity to diabetes. Nat Commun 2014, 5:4934.
27. Furukawa S., Fujita T., Shimabukuro M., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. JClin Invest 2004, 114:1752-1761.
28. Eckburg P.B., Bik E.M., Bernstein C.N., et al. Diversity of the human intestinal microbial flora. Science 2005, 308:1635-1638.
29. Sommer F., Backhed F. The gut microbiota-masters of host development and physiology. Nat Rev Microbiol 2013, 11:227-238.
30. Ley R.E., Backhed F., Turnbaugh P., et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005, 102:11070-11075.
31. Turnbaugh P.J., Hamady M., Yatsunenko T., et al. Acore gut microbiome in obese and lean twins. Nature 2009, 457:480-484.
32. Vijay-Kumar M., Aitken J.D., Carvalho F.A., et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010, 328:228-231.
33. Sokol H., Pigneur B., Watterlot L., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008, 105:16731-16736.
34. Kalliomaki M., Collado M.C., Salminen S., Isolauri E. Early differences in fecal microbiota composition in children may predict overweight. Am J Clin Nutr 2008, 87:534-538.
35. Fukuda S., Toh H., Hase K., et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 2011, 469:543-547.
36. Macfarlane S., Macfarlane G.T., Cummings J.H. Review article: prebiotics in the gastrointestinal tract. Aliment Pharmacol Ther 2006, 24:701-714.
37. de La Serre C.B., Ellis C.L., Lee J., et al. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastrointest Liver Physiol 2010, 299:G440-G448.
38. Cani P.D., Amar J., Iglesias M.A., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56:1761-1772.
39. Karlsson F.H., Tremaroli V., Nookaew I., et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013, 498:99-103.
40. Virdis A., Neves M.F., Duranti E., Bernini G., Taddei S. Microvascular endothelial dysfunction in obesity and hypertension. Curr Pharm Des 2013, 19:2382-2389.
41. Kobayasi R., Akamine E.H., Davel A.P., et al. Oxidative stress and inflammatory mediators contribute to endothelial dysfunction in high-fat diet-induced obesity in mice. JHypertens 2010, 28:2111-2119.
42. Sansbury B.E., Cummins T.D., Tang Y., et al. Overexpression of endothelial nitric oxide synthase prevents diet-induced obesity and regulates adipocyte phenotype. Circulation Res 2012, 111:1176-1189.
43. Krzyzanowska K., Mittermayer F., Kopp H.P., Wolzt M., Schernthaner G. Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women. JClin Endocrinol Metab 2004, 89:6277-6281.
44. Traupe T., Lang M., Goettsch W., et al. Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. JHypertens 2002, 20:2239-2245.
45. Mendizabal Y., Llorens S., Nava E. Reactivity of the aorta and mesenteric resistance arteries from the obese spontaneously hypertensive rat: effects of glitazones. Am J Physiol Heart Circ Physiol 2011, 301:H1319-H1330.
46. Hodnett B.L., Dearman J.A., Carter C.B., Hester R.L. Attenuated PGI2 synthesis in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 2009, 296:R715-R721.
47. Du X., Edelstein D., Obici S., et al. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. JClin Invest 2006, 116:1071-1080.
48. Weil B.R., Westby C.M., Van Guilder G.P., et al. Enhanced endothelin-1 system activity with overweight and obesity. Am J Physiol Heart Circ Physiol 2011, 301:H689-H695.
49. Parrinello G., Scaglione R., Pinto A., et al. Central obesity and hypertension: the role of plasma endothelin. Am J Hypertens 1996, 9:1186-1191.
50. Steinberg H.O., Chaker H., Leaming R., et al. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. JClin Invest 1996, 97:2601-2610.
51. Perticone F., Ceravolo R., Candigliota M., et al. Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes 2001, 50:159-165.
52. Grassi G., Seravalle G., Scopelliti F., et al. Structural and functional alterations of subcutaneous small resistance arteries in severe human obesity. Obesity 2010, 18:92-98.
53. Virdis A., Santini F., Colucci R., et al. Vascular generation of tumor necrosis factor-alpha reduces nitric oxide availability in small arteries from visceral fat of obese patients. JAm Coll Cardiol 2011, 58:238-247.
54. Nielsen S., Guo Z., Johnson C.M., Hensrud D.D., Jensen M.D. Splanchnic lipolysis in human obesity. JClin Invest 2004, 113:1582-1588.
55. Martin M.L., Jensen M.D. Effects of body fat distribution on regional lipolysis in obesity. JClin Invest 1991, 88:609-613.
56. Mathew M., Tay E., Cusi K. Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects. Cardiovasc Diabetol 2010, 9:9.
57. Kim Y.W., Kim J.Y., Lee S.K. Surgical removal of visceral fat decreases plasma free fatty acid and increases insulin sensitivity on liver and peripheral tissue in monosodium glutamate (MSG)-obese rats. JKorean Med Sci 1999, 14:539-545.
58. Gabriely I., Ma X.H., Yang X.M., et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process?. Diabetes 2002, 51:2951-2958.
59. Ybarra J., Blanco-Vaca F., Fernandez S., et al. The effects of liposuction removal of subcutaneous abdominal fat on lipid metabolism are independent of insulin sensitivity in normal-overweight individuals. Obesity Surg 2008, 18:408-414.
60. Klein S., Fontana L., Young V.L., et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. NEngl J Med 2004, 350:2549-2557.
61. Garanty-Bogacka B., Syrenicz M., Syrenicz A., et al. Serum markers of inflammation and endothelial activation in children with obesity-related hypertension. Neuro Endocrinol Lett 2005, 26:242-246.
62. Castro C., Tracy R.P., Deckelbaum R.J., Basch C.E., Shea S. Adiposity is associated with endothelial activation in healthy 2-3 year-old children. JPediatr Endocrinol Metab 2009, 22:905-914.
63. Verma S., Gupta M., Ridker P.M. Therapeutic targeting of inflammation in atherosclerosis: we are getting closer. Can J Cardiol 2012, 28:619-622.
64. De Nardo D., Latz E. NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol 2011, 32:373-379.
65. Vandanmagsar B., Youm Y.H., Ravussin A., et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011, 17:179-188.
66. Wen H., Gris D., Lei Y., et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 2011, 12:408-415.
67. Stienstra R., Joosten L.A., Koenen T., et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab 2010, 12:593-605.
68. Duewell P., Kono H., Rayner K.J., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361.
69. Odegaard J.I., Chawla A. Mechanisms of macrophage activation in obesity-induced insulin resistance. Nat Clin Pract Endocrinol Metab 2008, 4:619-626.